{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:11:53Z","timestamp":1787501513876,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10354-017-0595-x","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T08:54:55Z","timestamp":1504256095000},"page":"213-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology"],"prefix":"10.1007","volume":"168","author":[{"given":"Lyubomir A.","family":"Dourmishev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrina V.","family":"Guleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljubka G.","family":"Miteva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,1]]},"reference":[{"key":"595_CR1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"16","author":"OC Bruton","year":"1952","unstructured":"Bruton OC. Agammaglobulinemia. Pediatrics. 1952;16:722\u20138.","journal-title":"Pediatrics"},{"key":"595_CR2","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","volume":"1","author":"P Imbach","year":"1981","unstructured":"Imbach P, Barandun S, d\u2019Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228\u201331.","journal-title":"Lancet"},{"key":"595_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2165\/11537660-000000000-00000","volume":"24","author":"P Cherin","year":"2010","unstructured":"Cherin P, Cabane J. Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use. BioDrugs. 2010;24:211\u201323.","journal-title":"BioDrugs"},{"key":"595_CR4","doi-asserted-by":"publisher","first-page":"829751","DOI":"10.1155\/2011\/829751","volume":"2011","author":"M Baleva","year":"2011","unstructured":"Baleva M, Nikolov K. The role of intravenous immunoglobulin preparations in the treatment of systemic sclerosis. Int J Rheumatol. 2011;2011:829751.","journal-title":"Int J Rheumatol"},{"key":"595_CR5","first-page":"191","volume-title":"Plasmopheresis and Immunoglobulins","author":"K Nikolov","year":"2014","unstructured":"Nikolov K, Nikolova-Vlahova M, Baleva M. Side effects of intravenous immunoglobulins (IVIG). In: Allegro R, editor. Plasmopheresis and Immunoglobulins. New York: Nova; 2014. pp. 191\u2013204."},{"issue":"3","key":"595_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10875-007-9088-9","volume":"27","author":"VS Negi","year":"2007","unstructured":"Negi VS, Elluru S, Siberil S, et\u00a0al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J\u00a0Clin Immunol. 2007;27(3):233\u201345.","journal-title":"J Clin Immunol"},{"issue":"12","key":"595_CR7","first-page":"15879","volume":"8","author":"C Zhou","year":"2015","unstructured":"Zhou C, Huang M, Xie L, et al. IVIG inhibits TNF-\u03b1-induced MMP9 expression and activity in monocytes by suppressing NF-\u03baB and P38 MAPK activation. Int J Clin Exp Pathol. 2015;8(12):15879\u201386.","journal-title":"Int J Clin Exp Pathol"},{"issue":"12","key":"595_CR8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/j.1610-0387.2007.06554.x","volume":"5","author":"A Kuhn","year":"2007","unstructured":"Kuhn A, Sticherling M, Bonsmann G. Clinical manifestations of cutaneous lupus erythematosus. J\u00a0Dtsch Dermatol Ges. 2007;5(12):1124\u201337.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"595_CR9","first-page":"295","volume":"7","author":"A Corvetta","year":"1989","unstructured":"Corvetta A, Della Bitta R, Gabrielli A, et al. Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clin Exp Rheumatol. 1989;7(3):295\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"595_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0140-6736(99)01575-5","volume":"354","author":"JN Boletis","year":"1999","unstructured":"Boletis JN, Ioannidis JP, Boki KA, et\u00a0al. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet. 1999;354:569\u201370.","journal-title":"Lancet"},{"key":"595_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0049-0172(00)80018-9","volume":"29","author":"Y Levy","year":"2000","unstructured":"Levy Y, Sherer Y, George J, et\u00a0al. Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum. 2000;29:321\u20137.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"595_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10875-012-9816-7","volume":"33","author":"N Costa","year":"2013","unstructured":"Costa N, Pires AE, Gabriel AM, et al. Broadened T\u2011cell repertoire diversity in ivIg-treated SLE patients is also related to the individual status of regulatory T\u2011cells. J\u00a0Clin Immunol. 2013;33(2):349\u201360.","journal-title":"J Clin Immunol"},{"issue":"1","key":"595_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/09546630310018789","volume":"15","author":"M Goodfield","year":"2004","unstructured":"Goodfield M, Davison K, Bowden K. Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J\u00a0Dermatolog Treat. 2004;15(1):46\u201350.","journal-title":"J Dermatolog Treat"},{"issue":"Suppl 9","key":"595_CR14","first-page":"304","volume":"38","author":"JC Piette","year":"1995","unstructured":"Piette JC, Frances C, Roy S, et al. High-dose immunoglobulins in the treatment of refractory kg\/day for five consecutive days each month for a\u00a012-cutaneous lupus erythematosus: open trial in 5 patients. Arthritis Rheum. 1995;38(Suppl 9):304.","journal-title":"Arthritis Rheum"},{"issue":"2\u20133","key":"595_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s12016-009-8162-x","volume":"38","author":"J Esp\u00edrito Santo","year":"2010","unstructured":"Esp\u00edrito Santo J, Gomes MF, Gomes MJ, et\u00a0al. Intravenous immunoglobulin in lupus panniculitis. Clin Rev Allergy Immunol. 2010;38(2\u20133):307\u201318.","journal-title":"Clin Rev Allergy Immunol"},{"key":"595_CR16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s10067-006-0222-5","volume":"26","author":"CE Lampropoulos","year":"2007","unstructured":"Lampropoulos CE, Hughes GR. Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a\u00a0possible alternative. Clin Rheumatol. 2007;26:981\u20133.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"595_CR17","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/archderm.135.9.1124","volume":"135","author":"T G\u00e9n\u00e9reau","year":"1999","unstructured":"G\u00e9n\u00e9reau T, Chosidow O, Danel C, et al. High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol. 1999;135(9):1124\u20135.","journal-title":"Arch Dermatol"},{"issue":"6","key":"595_CR18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/00015550510037071","volume":"85","author":"A Kreuter","year":"2005","unstructured":"Kreuter A, Hyun J, Altmeyer P, et\u00a0al. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus. Acta Derm Venereol. 2005;85(6):545\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"595_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1177\/0961203316630116","volume":"25","author":"A Brasileiro","year":"2016","unstructured":"Brasileiro A, Fonseca Oliveira J, Pinheiro S, et\u00a0al. Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulin. Lupus. 2016;25(6):663\u20135.","journal-title":"Lupus"},{"issue":"1","key":"595_CR20","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.4081\/dr.2015.5804","volume":"7","author":"C Ky","year":"2015","unstructured":"Ky C, Swasdibutra B, Khademi S, et al. Efficacy of intravenous immunoglobulin Monotherapy in patients with cutaneous lupus Erythematosus: results of proof-of-concept study. Dermatol Reports. 2015;7(1):5804.","journal-title":"Dermatol Reports"},{"issue":"4","key":"595_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/096120339700600414","volume":"6","author":"O Pit\u00e0 De","year":"1997","unstructured":"De Pit\u00e0 O, Bellucci AM, Ruffelli M, et\u00a0al. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus. 1997;6(4):415\u20137.","journal-title":"Lupus"},{"issue":"6","key":"595_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ad.2011.10.013","volume":"103","author":"DE Cieza-D\u00edaz","year":"2012","unstructured":"Cieza-D\u00edaz DE, Avil\u00e9s-Izquierdo JA, Ceballos-Rodr\u00edguez C, et al. Refractory subacute cutaneous lupus erythematosus treated with rituximab. Actas Dermosifiliogr. 2012;103(6):555\u20137.","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"595_CR23","first-page":"255","volume":"73","author":"U Wollina","year":"1998","unstructured":"Wollina U, Looks A, Kammler H\u2011J. Intravenous immunoglobulin therapy in dermatology: overview and center experience. An Bras Dermatol. 1998;73(3):255\u20139.","journal-title":"An Bras Dermatol"},{"issue":"10","key":"595_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1046\/j.1365-4362.2002.01482.x","volume":"41","author":"LA Dourmishev","year":"2002","unstructured":"Dourmishev LA, Dourmishev AL, Schwartz RA. Dermatomyositis: cutaneous manifestations of its variants. Int J Dermatol. 2002;41(10):625\u201330.","journal-title":"Int J Dermatol"},{"key":"595_CR25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971\u201382.","journal-title":"Lancet"},{"issue":"5","key":"595_CR26","first-page":"880","volume":"34","author":"S Tansley","year":"2016","unstructured":"Tansley S, Shaddick G, Christopher-Stine L, et al. Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences. Clin Exp Rheumatol. 2016;34(5):880\u20134.","journal-title":"Clin Exp Rheumatol"},{"key":"595_CR27","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1172\/JCI117520","volume":"94","author":"M Basta","year":"1994","unstructured":"Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J\u00a0Clin Invest. 1994;94:1729\u201335.","journal-title":"J Clin Invest"},{"key":"595_CR28","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N\u00a0Engl J Med. 1993;329:1993\u20132000.","journal-title":"N Engl J Med"},{"issue":"7","key":"595_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1346-8138.1999.tb02026.x","volume":"26","author":"T Sadayama","year":"1999","unstructured":"Sadayama T, Miyagawa S, Shirai T. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. J\u00a0Dermatol. 1999;26(7):457\u20139.","journal-title":"J Dermatol"},{"key":"595_CR30","first-page":"2012","volume":"18","author":"L Shahani","year":"2012","unstructured":"Shahani L. Refractory calcinosis in a\u00a0patient with dermatomyositis: response to intravenous immune globulin. BMJ Case Rep. 2012;18:2012.","journal-title":"BMJ Case Rep"},{"key":"595_CR31","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1111\/j.1365-2133.2007.07891.x","volume":"156","author":"H Amano","year":"2007","unstructured":"Amano H, Nagai Y, Katada K, et al. Successful treatment of cutaneous lesions in juvenile dermatomyositis with high-dose intravenous immunoglobulin. Br J Dermatol. 2007;156:1390\u20132.","journal-title":"Br J Dermatol"},{"issue":"3","key":"595_CR32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s12013-014-9833-7","volume":"69","author":"G Imataka","year":"2014","unstructured":"Imataka G, Arisaka O. Long-term, high-dose intravenous immunoglobulin therapy in a\u00a0patient with banker-type juvenile dermatomyositis. Cell Biochem Biophys. 2014;69(3):747\u20138.","journal-title":"Cell Biochem Biophys"},{"issue":"1","key":"595_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12969-016-0112-6","volume":"14","author":"F Speth","year":"2016","unstructured":"Speth F, Haas J\u2011P, Hinze CH. Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a\u00a0report of 5 cases. Pediatr Rheumatol Online\u00a0J. 2016;14(1):52.","journal-title":"Pediatr Rheumatol Online J"},{"key":"595_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2174\/1874312901409010077","volume":"9","author":"JM Cafardi","year":"2015","unstructured":"Cafardi JM, Sami N. Intravenous immune globulin in Amyopathic Dermatomyositis \u2013 report of two cases and review of the literature. Open Rheumatol\u00a0J. 2015;9:77\u201381.","journal-title":"Open Rheumatol J"},{"issue":"6","key":"595_CR35","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1046\/j.1365-2230.1998.00378.x","volume":"23","author":"U Wollina","year":"1998","unstructured":"Wollina U, Looks A, Schneider R, et al. Disabling morphoea of childhood-beneficial effect of intravenous immunoglobulin therapy. Clin Exp Dermatol. 1998;23(6):292\u20133.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"595_CR36","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/art.20195","volume":"50","author":"Y Levy","year":"2004","unstructured":"Levy Y, Amital H, Langevitz P, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum. 2004;50(3):1005\u20137.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"595_CR37","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/rheumatology\/keh600","volume":"44","author":"Y Asano","year":"2005","unstructured":"Asano Y, Ihn H, Asashima N, et al. A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology (Oxford). 2005;44(6):824\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"595_CR38","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/j.1365-2133.2007.07777.x","volume":"156","author":"H Ihn","year":"2007","unstructured":"Ihn H, Mimura Y, Yazawa N, et al. High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol. 2007;156(5):1058\u201360.","journal-title":"Br J Dermatol"},{"issue":"2 Suppl 76","key":"595_CR39","first-page":"151","volume":"31","author":"K Takehara","year":"2013","unstructured":"Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol. 2013;31(2 Suppl 76):151\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"595_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10067-008-1062-2","volume":"28","author":"Z Szekanecz","year":"2009","unstructured":"Szekanecz Z, Aleksza M, Antal-Szalm\u00e1s P, et al. Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12\u00a0months: follow-up of immunopathological and clinical effects. Clin Rheumatol. 2009;28(3):347\u201350.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"595_CR41","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/0002-9343(72)90064-2","volume":"52","author":"GC Sharp","year":"1972","unstructured":"Sharp GC, Irvin WS, Tan EM, et\u00a0al. Mixed connective tissue disease \u2013 an apparently distinct rheumatic disease syndrome associated with a\u00a0specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148\u201359.","journal-title":"Am J Med"},{"issue":"4","key":"595_CR42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2133.1990.tb01462.x","volume":"123","author":"C Bodemer","year":"1990","unstructured":"Bodemer C, Teillac D, Le Bourgeois M, et\u00a0al. Efficacy of intravenous immunoglobulins in sclerodermatomyositis. Br J Dermatol. 1990;123(4):545\u20136.","journal-title":"Br J Dermatol"},{"issue":"1","key":"595_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1067\/mjd.2001.118539","volume":"46","author":"A Ulmer","year":"2002","unstructured":"Ulmer A, K\u00f6tter I, Pfaff A, et\u00a0al. Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease. J\u00a0Am Acad Dermatol. 2002;46(1):123\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"595_CR44","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2169\/internalmedicine.42.910","volume":"42","author":"M Matsuda","year":"2003","unstructured":"Matsuda M, Miki J, Oguchi K, et al. Fasciitis in mixed connective tissue disease successfully treated with high-dose intravenous immunoglobulin. Intern Med. 2003;42(9):910\u20131.","journal-title":"Intern Med"},{"issue":"1","key":"595_CR45","doi-asserted-by":"publisher","first-page":"CS1","DOI":"10.12659\/MSM.881308","volume":"17","author":"AP Rozin","year":"2011","unstructured":"Rozin AP, Egozi D, Ramon Y, et\u00a0al. Large leg ulcers due to autoimmune diseases. Med Sci Monit. 2011;17(1):CS1\u20137.","journal-title":"Med Sci Monit"},{"issue":"4","key":"595_CR46","doi-asserted-by":"publisher","first-page":"249","DOI":"10.5415\/apallergy.2013.3.4.249","volume":"3","author":"FR Palabrica","year":"2013","unstructured":"Palabrica FR, Kwong SL, Padua FR. Adverse events of intravenous immunoglobulin infusions: a\u00a0ten-year retrospective study. Asia Pac Allergy. 2013;3(4):249\u201356.","journal-title":"Asia Pac Allergy"},{"key":"595_CR47","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2340\/00015555-0249","volume":"87","author":"C Prins","year":"2007","unstructured":"Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol. 2007;87:206\u201318.","journal-title":"Acta Derm Venereol"},{"key":"595_CR48","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1212\/WNL.44.2.223","volume":"44","author":"MC Dalakas","year":"1994","unstructured":"Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223\u20136.","journal-title":"Neurology"},{"key":"595_CR49","doi-asserted-by":"publisher","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","volume":"121","author":"EA Sekul","year":"1994","unstructured":"Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259\u201362.","journal-title":"Ann Intern Med"},{"key":"595_CR50","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1056\/NEJM198602273140907","volume":"314","author":"AW Burks","year":"1986","unstructured":"Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N\u00a0Engl J Med. 1986;314:560\u20134.","journal-title":"N Engl J Med"},{"issue":"2","key":"595_CR51","first-page":"139","volume":"19","author":"S Dashti-Khavidaki","year":"2009","unstructured":"Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, et al. Adverse reactions of prophylactic intravenous immunoglobulin; A 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J\u00a0Investig Allergol Clin Immunol. 2009;19(2):139\u201345.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"9","key":"595_CR52","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00467-012-2172-2","volume":"27","author":"P Krug","year":"2012","unstructured":"Krug P, Boyer O, Balzamo E, et\u00a0al. Nephrotic syndrome in Kawasaki disease: a\u00a0report of three cases. Pediatr Nephrol. 2012;27(9):1547\u201350.","journal-title":"Pediatr Nephrol"},{"key":"595_CR53","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1102::AID-MUS2>3.0.CO;2-C","volume":"20","author":"BM Koffman","year":"1997","unstructured":"Koffman BM, Dalakas MC. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve. 1997;20:1102\u20137.","journal-title":"Muscle Nerve"},{"issue":"2","key":"595_CR54","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1001\/archderm.142.2.213","volume":"142","author":"G Vecchietti","year":"2006","unstructured":"Vecchietti G, Kerl K, Prins C, et al. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol. 2006;142(2):213\u20137.","journal-title":"Arch Dermatol"},{"issue":"3","key":"595_CR55","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/bjd.14200","volume":"174","author":"M Kurata","year":"2016","unstructured":"Kurata M, Horie C, Kano Y, et al. Pompholyx as a\u00a0clinical manifestation suggesting increased serum IgG levels in a\u00a0patient with drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms. Br J Dermatol. 2016;174(3):681\u20133.","journal-title":"Br J Dermatol"},{"key":"595_CR56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1478-7547-8-14","volume":"8","author":"G Blackhouse","year":"2010","unstructured":"Blackhouse G, Gaebel K, Xie F, et al. Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc. 2010;8:14.","journal-title":"Cost Eff Resour Alloc"},{"issue":"5","key":"595_CR57","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40273-015-0269-8","volume":"33","author":"N Bamrungsawad","year":"2015","unstructured":"Bamrungsawad N, Chaiyakunapruk N, Upakdee N, et al. Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand. Pharmacoeconomics. 2015;33(5):521\u201331.","journal-title":"Pharmacoeconomics"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-017-0595-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-017-0595-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-017-0595-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T06:57:45Z","timestamp":1692946665000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-017-0595-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,1]]},"references-count":57,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["595"],"URL":"https:\/\/doi.org\/10.1007\/s10354-017-0595-x","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,1]]},"assertion":[{"value":"19 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.A.\u00a0Dourmishev, D.V.\u00a0Guleva, and L.G.\u00a0Miteva declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}